France’s heavily-indebted laboratory groups are poised for a wave of restructurings, after a government-led audit of the sector recommended measures including profit caps to slash outsized margins.
The recommendations published last month by the government body in charge of auditing France’s health sector said that “measures must be taken to bring the cost of biology back to a fair price”, including “the introduction of profitability-based regulation”.
France’s medical laboratory sector includes some heavily-indebted companies that have been acquired through leveraged buyouts in recent years, as private equity firms target an industry that generates margins that are much higher than the rest of France’s broader medical sector.
您已閱讀21%（734字），剩余79%（2802字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。